This disclosure relates to novel compounds containing an HS releasing moiety and a nitric oxide (NO) releasing moiety covalently linked with a core (e.g. a salicylic acid moiety) and the use of such compounds in treating inflammatory diseases including cancers. Therapeutic potency of these compounds is significantly higher than NSAIDs containing a HS releasing moiety alone (HS NSAIDs) and NSAID containing a NO releasing moiety alone (NO NSAIDs). The compounds in addition exhibit reduced side effect e.g. reduced stomach ulcers upon administration.
